Dentons advised Immunic, Inc. on its private placement financing of up to US$400 million, including US$200 million in initial proceeds and the potential for an additional US$200 million.
The financing is expected to support the completion of Immunic’s Phase III clinical trials and its transition to a commercial organization, advancing the company’s long-term growth and strategic objectives.
Dentons was pleased to support Immunic on these transactions with a Venture Technology team led by Ilan Katz, Grant Levine, Zachary Weiss, and Madeline Hunter in New York.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
